Articles with public access mandates - Prof. Dr. med. Axel S. MerseburgerLearn more
Not available anywhere: 15
Pan-cancer analysis of the mediator complex transcriptome identifies CDK19 and CDK8 as therapeutic targets in advanced prostate cancer
J Brägelmann, N Klümper, A Offermann, A Von Maessenhausen, D Böhm, ...
Clinical Cancer Research 23 (7), 1829-1840, 2017
Mandates: German Research Foundation
Discovery and validation of urinary biomarkers for detection of renal cell carcinoma
M Frantzi, J Metzger, RE Banks, H Husi, J Klein, M Dakna, W Mullen, ...
Journal of proteomics 98, 44-58, 2014
Mandates: Cancer Research UK
Apoptosis gene polymorphisms and risk of prostate cancer: a hospital-based study of German patients treated with brachytherapy
A Meyer, I Coinac, N Bogdanova, N Dubrowinskaja, N Turmanov, ...
Urologic Oncology: Seminars and Original Investigations 31 (1), 74-81, 2013
Mandates: US National Institutes of Health
Increased mediator complex subunit CDK19 expression associates with aggressive prostate cancer
F Becker, V Joerg, MC Hupe, D Roth, R Krupar, V Lubczyk, R Kuefer, ...
International journal of cancer 146 (2), 577-588, 2020
Mandates: German Research Foundation
TRIM24 as an independent prognostic biomarker for prostate cancer
A Offermann, D Roth, MC Hupe, S Hohensteiner, F Becker, V Joerg, ...
Urologic Oncology: Seminars and Original Investigations 37 (9), 576. e1-576. e10, 2019
Mandates: German Research Foundation
Histomorphological analysis of false positive PI-RADS 4 and 5 lesions
MC Hupe, A Offermann, L Tharun, A Fürschke, A Frydrychowicz, ...
Urologic Oncology: Seminars and Original Investigations 38 (7), 636. e7-636. e12, 2020
Mandates: German Research Foundation
Analysis of tripartite motif (TRIM) family gene expression in prostate cancer bone metastases
A Offermann, D Kang, C Watermann, A Weingart, MC Hupe, A Saraji, ...
Carcinogenesis 42 (12), 1475-1484, 2021
Mandates: German Research Foundation
HYAL4-V1/Chondroitinase (Chase) drives gemcitabine resistance and predicts chemotherapy failure in patients with bladder cancer
SL Hasanali, DS Morera, RR Racine, M Hennig, S Ghosh, LE Lopez, ...
Clinical Cancer Research 27 (15), 4410-4421, 2021
Mandates: US Department of Defense, US National Institutes of Health
Targeting cyclin-dependent kinase 7—association between CDK7 and pMED1 expression in prostate cancer tissue
FO Paulsen, D Kang, F Becker, D Roth, V Joerg, E Dreyer, MC Roesch, ...
Carcinogenesis 43 (8), 779-786, 2022
Mandates: German Research Foundation
SDCT2 AS A FUNCTIONAL BIOMARKER OF RENAL CELL CARCINOMA: MP39-15
A Jordan, M Hennig, A Merseburger, M Hupe, M Kramer, M Soloway, ...
Journal of Urology 197 (4), e499, 2017
Mandates: US National Institutes of Health
EXPRESSION AND FUNCTION OF A NOVEL CHONDROITINASE IN BLADDER CANCER: MP48-01
M Hupe, S Lokeshwar, M Hennig, D Schimmelpfennig, M Kramer, ...
Journal of Urology 197 (4), e636-e637, 2017
Mandates: US National Institutes of Health
1836P Blood based biomarkers identify metastatic castration-resistant prostate cancer (mCRPC) with the greatest benefit from continuing enzalutamide (ENZ) beyond progression in …
MR Vico, D Wetterskog, S Thakali, F Orlando, AK Jayaram, O Vainauskas, ...
Annals of Oncology 34, S994, 2023
Mandates: Cancer Research UK
MP03-03 TARGETING V1/CHASE TO OVERCOME GEMCITABINE RESISTANCE
S Sarcan, DS Morera, MC Hupe, K Aguilar, A Sharma, S Alexander, ...
Journal of Urology 207 (Supplement 5), e19, 2022
Mandates: US Department of Defense
HYAL4: A MOLECULAR MARKER AND DETERMINANT OF BLADDER CANCER PROGRESSION: MP88-18
MJP Hennig, SD Lokeshwar, SN Wilson, J Knapp, MC Hupe, AR Jordan, ...
Journal of Urology 195 (4), e1135-e1136, 2016
Mandates: US National Institutes of Health
HYAL4: A NEW PLAYER IN BLADDER CANCER PROGRESSION AND DIAGNOSIS
J Knapp, S Lokeshwar, M Gosalbez, H Yu, M Kramer, A Merseburger, ...
The Journal of Urology 181 (4S), 417-417, 2009
Mandates: US National Institutes of Health
Available somewhere: 42
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
W Abida, A Patnaik, D Campbell, J Shapiro, AH Bryce, R McDermott, ...
Journal of Clinical Oncology 38 (32), 3763-3772, 2020
Mandates: US Department of Defense, US National Institutes of Health
Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 …
W Abida, D Campbell, A Patnaik, JD Shapiro, B Sautois, NJ Vogelzang, ...
Clinical Cancer Research 26 (11), 2487-2496, 2020
Mandates: US Department of Defense, US National Institutes of Health
Expression of prostate-specific membrane antigen (PSMA) on biopsies is an independent risk stratifier of prostate cancer patients at time of initial diagnosis
MC Hupe, C Philippi, D Roth, C Kümpers, J Ribbat-Idel, F Becker, V Joerg, ...
Frontiers in oncology 8, 623, 2018
Mandates: German Research Foundation
Association of hyaluronic acid family members (HAS1, HAS2, and HYAL‐1) with bladder cancer diagnosis and prognosis
MW Kramer, DO Escudero, SD Lokeshwar, R Golshani, OO Ekwenna, ...
Cancer 117 (6), 1197-1209, 2011
Mandates: US National Institutes of Health
Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study
N Agarwal, K McQuarrie, A Bjartell, S Chowdhury, ...
The Lancet Oncology 20 (11), 1518-1530, 2019
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program